“Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease”
- ACEi, angiotensin converting enzyme inhibitors
- ARB, angiotensin receptor blocker
- CV, cardiovascular
- MI, myocardial infarction
Statistics from Altmetric.com
Conflict of interest: Professor Hall has received research grants from Astra-Zeneca, Servier UK, and Sanofi-Aventis UK; has received honoraria from Astra-Zeneca and Servier UK; and has been paid consultant fees by Servier UK. Dr Strauss has received honoraria from Sanofi-Aventis, Pfizer, Abbott, and Tanabe; has served as an expert witness for Sanofi-Aventis; and has served as a consultant/advisory board member for Sanofi-Aventis and Pfizer.